EYE PATHOLOGIES IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (CASE REPORT AND LITERARY ANALYSIS)
https://doi.org/10.21516/2072-0076-2018-11-3-50-54
Abstract
In addition to the classic Coats’ disease characterized by retinal vascular telangiectasias and aneurysmal dilatations surrounded by yellowish intra- and subretinal exudates and developing in somatically healthy children, Coats’-like retinal changes can occur in a number of systemic diseases and complicate the course of other eye pathologies. One of the diseases that occur with Coats’-like exudative vasculopathy is facioscapulohumeral muscular dystrophy, or Landouzy - Dejerine disease. Systemic manifestations of this pathology are the myodystrophic process, which usually affects muscles of the face and arms and distal muscles of the legs, as well as sensorineural hearing loss, respiratory failure, cardiac arrhythmia, in the infantile form - mental retardation and episyndrome. The paper describes two clinical cases involving children with facioscapulohumeral muscular dystrophy, presents the results of treatment, and discusses the importance of a systematic approach in examining patients with Coats’-like retinal changes. For citation: Denisova E.V., Katargina L.A., Kogoleva L.V., Belova M.V., Osipova N.A., Fedoseeva E.V. Eye pathologies in facioscapulohumeral muscular dystrophy (case report and literary analysis). Russian ophthalmological journal. 2018; 11 (3): 50-4 (In Russian). doi: 10.21516/2072-0076-2018-11-3-50-54
About the Authors
E. V. Denisova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
L. A. Katargina
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
L. V. Kogoleva
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
M. V. Belova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
N. A. Osipova
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
E. V. Fedoseeva
Moscow Helmholtz Research Institute of Eye Diseases
Russian Federation
Russian Federation
References
1. Мосин И. М. Болезнь Коатса. В кн. Шамшинова А.М., ред. Наследственные и врожденные заболевания сетчатки и зрительного нерва. Москва: Медицина; 2001: 297-324.
2. Recchia F.M. Coats Disease. In: Harnett M.E., ed. Pediatric Retina. 2nd ed. Philadelphia: Lippincott Williams Wilkins; 2013: 616-25.
3. Tawil R., Van Der Maarel S. M. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006; 34(1): 1-15.
4. Tawil R., Kissel J. T., Heatwole C., et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy. Neurology. 2015; 85(4): 357-64.
5. Bindoff L. A., Mjellem N., Sommerfelt K., et al. Severe fascioscapulohumeral muscular dystrophy presenting with Coats' disease and mental retardation. Neuromuscul. Disord. 2006; 16(9-10): 559-63.
6. Fitzsimons R. B., Gurwin E. B., Bird A. C. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain. 1987; 110 (Pt 3): 631-48.
7. Gurwin E.B., Fitzsimons R.B., Sehmi K.S., Bird A.C. Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness. Arch. Ophthalmol. 1985; 103(11): 1695-700.
8. Pauleikhoff D., Bornfeld N., Bird A.C., Wessing A. Severe visual loss associated with retinal telangiectasis and facioscapulohumeral muscular dystrophy. Graefes Arch. Clin. Exp. Ophthalmol. 1992; 230(4): 362-5.
9. Gaillard M. C., Mataftsi A., Balmer A., Houghton S., Munier F. L. Ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes. Retina. 2014; 34(11): 2275-81. doi: 10.1097/IAE.0000000000000248
10. Henry C. R., Sisk R. A., Tzu J. H., et al. Long-term follow-up of intravitreal bevacizumab for the treatment of pediatric retinal and choroidal diseases. J. AAPOS. 2015; 19(6): 541-8. doi: 10.1016/j.jaapos.2015.09.006
11. Kaul S., Uparkar M., Mody K., et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Сoats' disease in children. Indian J. Ophthalmol. 2010; 58(1): 76-8. doi: 10.4103/0301-4738.58480
12. Lin C. J., Hwang J.F., Chen Y. T., Chen S. N. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2010; 30(4): 617-22. doi: 10.1097/IAE.0b013e3181c2e0b7
13. Ramasubramanian A., Shields C. L. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br. J. Ophthalmol. 2012; 96(3): 356-9. doi: 10.1136/bjophthalmol-2011-300141
14. Ray R., Barañano D. E., Hubbard G. B. Treatment of Coats' disease with intravitreal bevacizumab. Br. J. Ophthalmol. 2013; 97(3): 272-7. doi: 10.1136/bjophthalmol-2012-302250
15. Villegas V. M., Gold A. S., Berrocal A. M., Murray T. G. Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin. Ophthalmol. 2014; 16(8): 973-6. doi: 10.2147/OPTH.S62816
16. Zheng X.X., Jiang Y.R. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease. Graefes Arch. Clin. Exp. Ophthalmol. 2014; 252(1): 35-42. doi: 10.1007/s00417-013-2409-1
Review
For citations:
Denisova E.V., Katargina L.A., Kogoleva L.V., Belova M.V., Osipova N.A., Fedoseeva E.V. EYE PATHOLOGIES IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (CASE REPORT AND LITERARY ANALYSIS). Russian Ophthalmological Journal. 2018;11(3):50-54. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-3-50-54
Views:
1241
Email this article 